Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer

drexplorer: A tool to explore dose–response relationships and drug–drug interactions

(2015) Pan Tong et al.   BIOINFORMATICS

An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2

(2015) R. J. G. Cardnell et al.   CLINICAL CANCER RESEARCH

A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG–ACRIN Cancer Research Group (E2511)

(2015) Taofeek K. Owonikoko et al.   LUNG CANCER

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

AMP-Activated Protein Kinase: Maintaining Energy Homeostasis at the Cellular and Whole-Body Levels

(2014) D. Grahame Hardie   Annual Review of Nutrition

Small cell lung cancer: Where do we go from here?

(2014) Lauren Averett Byers et al.   CANCER

In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA

(2014) Dexin Kong et al.   INVESTIGATIONAL NEW DRUGS

Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis

(2014) Shigeki Umemura et al.   Journal of Thoracic Oncology

A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

(2014) T. Mazumdar et al.   MOLECULAR CANCER THERAPEUTICS

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

(2013) Carolyn D. Britten   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?

(2013) Peter Bouwman et al.   CLINICAL CANCER RESEARCH

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

(2013) R. J. Cardnell et al.   CLINICAL CANCER RESEARCH

Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases

(2013) Matt Addie et al.   JOURNAL OF MEDICINAL CHEMISTRY

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

(2013) H. Ebi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

α-SNAP inhibits AMPK signaling to reduce mitochondrial biogenesis and dephosphorylates Thr172 in AMPKα in vitro

(2013) Lifu Wang et al.   Nature Communications

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

AMPK mediates a pro-survival autophagy downstream of PARP-1 activation in response to DNA alkylating agents

(2012) Jing Zhou et al.   FEBS LETTERS

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

PARP-1 Modulation of mTOR Signaling in Response to a DNA Alkylating Agent

(2012) Chantal Éthier et al.   PLoS One

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

(2012) Lauren Averett Byers et al.   Cancer Discovery

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

(2012) Ashish Juvekar et al.   Cancer Discovery

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma

(2011) Tina Cascone et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

(2011) V Serra et al.   ONCOGENE

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

(2011) N. Ilic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

(2011) Matthew T. Burger et al.   ACS Medicinal Chemistry Letters

Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma

(2010) B. E. Schaffer et al.   CANCER RESEARCH

PP2A Mediated AMPK Inhibition Promotes HSP70 Expression in Heat Shock Response

(2010) Ting Wang et al.   PLoS One

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

(2009) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA